Advances in superenzyme gene therapy in penile rehabilitation.
- Author:
Feng QIN
1
;
Wang RUN
;
Jiu-Hong YUAN
Author Information
1. Research Center of Regenerative Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China. stinphen@163.com
- Publication Type:Journal Article
- MeSH:
Enzyme Therapy;
Epoprostenol;
Erectile Dysfunction;
rehabilitation;
therapy;
Genetic Therapy;
methods;
Humans;
Male;
Penile Erection;
Penis;
Prostaglandin-Endoperoxide Synthases;
metabolism
- From:
National Journal of Andrology
2013;19(4):350-354
- CountryChina
- Language:Chinese
-
Abstract:
Erectile dysfunction (ED) is an almost unavoidable complication of radical prostatectomy. At present, though the concept of penile rehabilitation (PR) is accepted by most clinicians, the outcomes of erectile function recovery vary widely. Prostacyclin (PGI2) is a prostanoid and a main vasoprotectant which induces smooth muscle relaxation, but not used for replacement therapy because of its high unstability. SuperEnzyme is capable of continuous, specific and targeted promotion of PGI2 synthesis, and helps PR in ED patients after radical prostatectomy. SuperEnzyme gene therapy has a promising prospect for PR and the management of ED. This review updates SuperEnzyme gene therapy in PR.
